| Autor: |
Greg Knoll, Bram Rochwerg, François Lauzier, Marat Slessarev, Michaël Chasse, Karen E A Burns, Alexis F Turgeon, John Gordon Boyd, Frédérick D'Aragon, Shane English, Matthew Weiss, Maureen Meade, Sonny Dhanani, Marie-Hélène Masse, François-Martin Carrier, Steven Hanna, Andrew Healey, Simon J W Oczkowski, Anne-Julie Frenette, Anique Ducharme, Prosanto Chaudhury, Markus Selzner, Ruth Breau, Mélanie Masse, Héloïse Cardinal, Brigitte Bolduc, Caroline Lamarche, Etienne Couture, Sandra Holdsworth, Liz Bertholz, Heather Talbot, Patrick Luke, M Khaled Shamseddin, Jeffrey Zaltzman, Darin Treleaven |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
BMJ Open, Vol 14, Iss 6 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2044-6055 |
| DOI: |
10.1136/bmjopen-2024-086777 |
| Popis: |
Introduction Most solid organ transplants originate from donors meeting criteria for death by neurological criteria (DNC). Within the organ donor, physiological responses to brain death increase the risk of ischaemia reperfusion injury and delayed graft function. Donor preconditioning with calcineurin inhibition may reduce this risk.Methods and analysis We designed a multicentre placebo-controlled pilot randomised trial involving nine organ donation hospitals and all 28 transplant programmes in the Canadian provinces of Ontario and Québec. We planned to enrol 90 DNC donors and their approximately 324 organ recipients, totalling 414 participants. Donors receive an intravenous infusion of either tacrolimus 0.02 mg/kg over 4 hours prior to organ retrieval, or a matching placebo, while monitored in an intensive care unit for any haemodynamic changes during the infusion. Among all study organ recipients, we record measures of graft function for the first 7 days in hospital and we will record graft survival after 1 year. We examine the feasibility of this trial with respect to the proportion of all eligible donors enrolled and the proportion of all eligible transplant recipients consenting to receive a CINERGY organ transplant and to allow the use of their health data for study purposes. We will report these feasibility outcomes as proportions with 95% CIs. We also record any barriers encountered in the launch and in the implementation of this trial with detailed source documentation.Ethics and dissemination We will disseminate trial results through publications and presentations at participating sites and conferences. This study has been approved by Health Canada (HC6-24-c241083) and by the Research Ethics Boards of all participating sites and in Québec (MP-31-2020-3348) and Clinical Trials Ontario (Project #3309).Trial registration number NCT05148715. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
